Meclofenamic acid

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (5)Transporters (2)

Targets (5)Transporters (2)Biointeractions (7)

Identification

Name

Meclofenamic acid

Accession Number

DB00939 (APRD01090)

Type

Small Molecule

Groups

Approved, Vet Approved

Description

A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Acide meclofenamique

Acido meclofenamico

Acidum meclofenamicum

Meclofenamate

N-(2,6-Dichloro-3-methylphenyl)anthranilic acid

N-(2,6-Dichloro-m-tolyl)anthranilic acid

N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid

External IDs

CI 583 / CI-583 / Cl 583 / INF 4668 / INF-4668

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Meclofenamate sodium	94NJ818U2W	67254-91-5	QHJLLDJTVQAFAN-UHFFFAOYSA-M	Details

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Meclofenamate Sodium	Capsule	50 mg/1	Oral	Mylan Pharmaceuticals	1986-09-03	Not applicable	US
Meclofenamate Sodium	Capsule	100 mg/1	Oral	Mylan Pharmaceuticals	1986-09-03	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Ethos	Yung Shin
Eucome	U-Liang
Meclomen	Pfizer

Brand mixtures

Not Available

Categories

UNII

48I5LU4ZWD

CAS number

644-62-2

Weight

Average: 296.149
Monoisotopic: 295.016684015

Chemical Formula

C₁₄H₁₁Cl₂NO₂

InChI Key

SBDNJUWAMKYJOX-UHFFFAOYSA-N

InChI

InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)

IUPAC Name

2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid

SMILES

CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1

Pharmacology

Indication

For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.

Structured Indications

Pharmacodynamics

Meclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.

Mechanism of action

The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Prostaglandin G/H synthase 1	Protein	yes	inhibitor	Human	P23219	details
Prostaglandin G/H synthase 2	Protein	yes	inhibitor	Human	P35354	details
Arachidonate 5-lipoxygenase	Protein	yes	inhibitor	Human	P09917	details
Potassium voltage-gated channel subfamily KQT member 2	Protein	unknown	other	Human	O43526	details
Potassium voltage-gated channel subfamily KQT member 3	Protein	unknown	other	Human	O43525	details

Absorption

Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (C_max) decreased fourfold and the time to C_max was delayed by 3 hours.

Volume of distribution

9.1 to 43.2 L

Protein binding

Greater than 99% bound to plasma proteins over a wide drug concentration range.

Metabolism

Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.

Route of elimination

Other metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.

Half life

In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.

Clearance

Oral cl=206 mL/min

Toxicity

After a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Meclofenamic acid may increase the anticoagulant activities of Abciximab.	Approved
Acebutolol	Meclofenamic acid may decrease the antihypertensive activities of Acebutolol.	Approved
Aceclofenac	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aceclofenac.	Approved
Acenocoumarol	Meclofenamic acid may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acetylsalicylic acid.	Approved, Vet Approved
Aclarubicin	Meclofenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.	Investigational
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Meclofenamic acid.	Approved
Alclometasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aldosterone.	Experimental
Alendronic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.	Approved
Aliskiren	Meclofenamic acid may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alprenolol	Meclofenamic acid may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Meclofenamic acid.	Approved, Investigational
Amcinonide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Amcinonide.	Approved
Amikacin	Meclofenamic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.	Approved, Vet Approved
Amiloride	Meclofenamic acid may decrease the antihypertensive activities of Amiloride.	Approved
Amrubicin	Meclofenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.	Approved, Investigational
Ancrod	Meclofenamic acid may increase the anticoagulant activities of Ancrod.	Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HMPL-004.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 4-Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anecortave.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anisodamine.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.	Approved
Antithrombin III human	Meclofenamic acid may increase the anticoagulant activities of Antithrombin III human.	Approved
Apixaban	Meclofenamic acid may increase the anticoagulant activities of Apixaban.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acetovanillone.	Investigational
Apramycin	Meclofenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Apremilast.	Approved, Investigational
Arbekacin	Meclofenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved
Ardeparin	Meclofenamic acid may increase the anticoagulant activities of Ardeparin.	Approved, Withdrawn
Argatroban	Meclofenamic acid may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Meclofenamic acid may decrease the antihypertensive activities of Arotinolol.	Approved
Atenolol	Meclofenamic acid may decrease the antihypertensive activities of Atenolol.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid.	Approved
Balsalazide	Meclofenamic acid may increase the nephrotoxic activities of Balsalazide.	Approved, Investigational
Becaplermin	Meclofenamic acid may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Beclomethasone dipropionate.	Approved, Investigational
Befunolol	Meclofenamic acid may decrease the antihypertensive activities of Befunolol.	Experimental
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Meclofenamic acid.	Approved, Investigational
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid.	Approved
Benoxaprofen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benoxaprofen.	Withdrawn
Beraprost	The therapeutic efficacy of Beraprost can be decreased when used in combination with Meclofenamic acid.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Meclofenamic acid may decrease the antihypertensive activities of Betaxolol.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betulinic Acid.	Investigational
Bevantolol	Meclofenamic acid may decrease the antihypertensive activities of Bevantolol.	Approved
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meclofenamic acid.	Approved, Investigational
Bisoprolol	Meclofenamic acid may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Meclofenamic acid may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Meclofenamic acid may decrease the antihypertensive activities of Bopindolol.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bromfenac.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bucillamine.	Investigational
Bucindolol	Meclofenamic acid may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide.	Approved
Bufuralol	Meclofenamic acid may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumetanide	Meclofenamic acid may decrease the diuretic activities of Bumetanide.	Approved
Bupranolol	Meclofenamic acid may decrease the antihypertensive activities of Bupranolol.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Candoxatril is combined with Meclofenamic acid.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Captopril is combined with Meclofenamic acid.	Approved
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meclofenamic acid.	Approved
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid.	Approved, Vet Approved, Withdrawn
Carteolol	Meclofenamic acid may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Meclofenamic acid may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Castanospermine.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Celecoxib.	Approved, Investigational
Celiprolol	Meclofenamic acid may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Certoparin	Meclofenamic acid may increase the anticoagulant activities of Certoparin.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid.	Approved, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.	Approved, Vet Approved
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trisalicylate-choline.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Cilazapril is combined with Meclofenamic acid.	Approved
Cinoxacin	Meclofenamic acid may increase the neuroexcitatory activities of Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.	Approved, Investigational
Citric Acid	Meclofenamic acid may increase the anticoagulant activities of Citric Acid.	Nutraceutical, Vet Approved
Clobetasol	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol.	Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol propionate.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clodronate.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clonixin.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortisone acetate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortisone acetate.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Curcumin.	Investigational
Cyclosporine	Meclofenamic acid may increase the nephrotoxic activities of Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	Meclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dalteparin	Meclofenamic acid may increase the anticoagulant activities of Dalteparin.	Approved
Darexaban	Meclofenamic acid may increase the anticoagulant activities of Ym150.	Investigational
Daunorubicin	Meclofenamic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox.	Approved, Investigational
Desirudin	Meclofenamic acid may increase the anticoagulant activities of Desirudin.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.	Approved
Desoximetasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoximetasone.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meclofenamic acid.	Approved
Dextran	Meclofenamic acid may increase the anticoagulant activities of Dextran.	Approved, Vet Approved
Dextran 40	Meclofenamic acid may increase the anticoagulant activities of Dextran 40.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid.	Approved, Vet Approved
Dicoumarol	Meclofenamic acid may increase the anticoagulant activities of Dicoumarol.	Approved
Diflorasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Diflorasone.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid.	Approved
Difluocortolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluocortolone.	Approved
Difluprednate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluprednate.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid.	Approved
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Meclofenamic acid.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meclofenamic acid.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meclofenamic acid.	Approved
Doxorubicin	Meclofenamic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.	Approved, Investigational
Drospirenone	Meclofenamic acid may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Duvelisib.	Investigational
E-6201	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with E6201.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ebselen.	Investigational
Edetic Acid	Meclofenamic acid may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Meclofenamic acid may increase the anticoagulant activities of Edoxaban.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Meclofenamic acid.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Enalaprilat is combined with Meclofenamic acid.	Approved
Enoxacin	Meclofenamic acid may increase the neuroexcitatory activities of Enoxacin.	Approved
Enoxaparin	Meclofenamic acid may increase the anticoagulant activities of Enoxaparin.	Approved
Epirizole	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Epirizole.	Approved
Epirubicin	Meclofenamic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.	Approved
Eplerenone	Meclofenamic acid may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid.	Approved
Equilenin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilin.	Approved
Esmolol	Meclofenamic acid may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone sulfate.	Approved
Etacrynic acid	Meclofenamic acid may decrease the diuretic activities of Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid.	Approved, Investigational
Ethyl biscoumacetate	Meclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etofenamate.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fenbufen.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid.	Approved
Fleroxacin	Meclofenamic acid may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Meclofenamic acid.	Approved, Withdrawn
Fludrocortisone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fludrocortisone.	Approved
Fluindione	Meclofenamic acid may increase the anticoagulant activities of Fluindione.	Investigational
Flumequine	Meclofenamic acid may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunisolide.	Approved, Investigational
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluorometholone.	Approved
Fluprednidene	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednidene.	Approved, Withdrawn
Flurandrenolide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide.	Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid.	Approved, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone Propionate.	Approved
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Meclofenamic acid.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Meclofenamic acid may increase the anticoagulant activities of Fondaparinux.	Investigational
Fondaparinux sodium	Meclofenamic acid may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Meclofenamic acid.	Approved
Framycetin	Meclofenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	Meclofenamic acid may decrease the diuretic activities of Furosemide.	Approved, Vet Approved
Gabexate	Meclofenamic acid may increase the anticoagulant activities of Gabexate.	Investigational
Gatifloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Meclofenamic acid.	Approved, Withdrawn
Gemifloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Meclofenamic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Meclofenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Meclofenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
Grepafloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Grepafloxacin.	Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HE3286.	Investigational
Heparin	Meclofenamic acid may increase the anticoagulant activities of Heparin.	Approved, Investigational
Higenamine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Higenamine.	Investigational
Hydralazine	Meclofenamic acid may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid.	Approved, Vet Approved
Hydrocortisone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid.	Approved
Ibandronate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.	Approved, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuproxam.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant.	Approved
Idarubicin	Meclofenamic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.	Approved
Iloprost	The therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Imidapril is combined with Meclofenamic acid.	Investigational
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.	Approved
Indenolol	Meclofenamic acid may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Indoprofen.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.	Approved, Investigational
Isoxicam	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Isoxicam.	Withdrawn
Kanamycin	Meclofenamic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Kebuzone.	Experimental
Ketoprofen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid.	Approved
Labetalol	Meclofenamic acid may decrease the antihypertensive activities of Labetalol.	Approved
Landiolol	Meclofenamic acid may decrease the antihypertensive activities of Aop200704.	Investigational
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Meclofenamic acid.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Leflunomide.	Approved, Investigational
Lepirudin	Meclofenamic acid may increase the anticoagulant activities of Lepirudin.	Approved
Levobunolol	Meclofenamic acid may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Limaprost	The therapeutic efficacy of Limaprost can be decreased when used in combination with Meclofenamic acid.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Meclofenamic acid.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisofylline.	Investigational
Lithium	The serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.	Approved
Lomefloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Lomefloxacin.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loxoprofen.	Approved
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lumiracoxib.	Approved, Investigational
Magnesium salicylate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate.	Approved
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid.	Approved
ME-609	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with ME-609.	Investigational
Medrysone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.	Approved, Vet Approved
Mesalazine	Meclofenamic acid may increase the nephrotoxic activities of Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Metamizole.	Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.	Approved
Methylprednisolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone.	Approved, Vet Approved
Metipranolol	Meclofenamic acid may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.	Approved
Metoprolol	Meclofenamic acid may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Metrizamide	Meclofenamic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.	Approved
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Meclofenamic acid.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mizoribine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Meclofenamic acid.	Approved
Mometasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Meclofenamic acid.	Approved
Moxifloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nabumetone.	Approved
Nadolol	Meclofenamic acid may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	Meclofenamic acid may increase the anticoagulant activities of Nadroparin.	Approved
Nafamostat	Meclofenamic acid may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Meclofenamic acid.	Approved
Nalidixic Acid	Meclofenamic acid may increase the neuroexcitatory activities of Nalidixic Acid.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid.	Approved, Vet Approved
NCX 1022	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 1022.	Investigational
NCX 4016	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 4016.	Investigational
Neamine	Meclofenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Neomycin	Meclofenamic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nepafenac.	Approved
Netilmicin	Meclofenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nitroaspirin.	Investigational
Norfloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Norfloxacin.	Approved
Ofloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Ofloxacin.	Approved
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oleoyl estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.	Approved
Olsalazine	Meclofenamic acid may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Omacetaxine mepesuccinate.	Approved
Omapatrilat	The risk or severity of adverse effects can be increased when Omapatrilat is combined with Meclofenamic acid.	Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.	Approved
Oxprenolol	Meclofenamic acid may decrease the antihypertensive activities of Oxprenolol.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxyphenbutazone.	Withdrawn
Pamidronate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parecoxib.	Approved
Paromomycin	Meclofenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.	Approved, Investigational
Pazufloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Pefloxacin.	Approved
Penbutolol	Meclofenamic acid may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentosan Polysulfate	Meclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Meclofenamic acid.	Approved
Phenindione	Meclofenamic acid may increase the anticoagulant activities of Phenindione.	Approved
Phenprocoumon	Meclofenamic acid may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid.	Approved, Investigational
Pindolol	Meclofenamic acid may decrease the antihypertensive activities of Pindolol.	Approved
Pirarubicin	Meclofenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.	Investigational
Piretanide	Meclofenamic acid may decrease the diuretic activities of Piretanide.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirfenidone.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.	Approved, Investigational
Plicamycin	Meclofenamic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.	Approved, Withdrawn
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Meclofenamic acid.	Approved
Practolol	Meclofenamic acid may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Meclofenamic acid.	Approved
Prasterone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone.	Approved, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with dehydroepiandrosterone sulfate.	Investigational
Prednicarbate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednicarbate.	Approved
Prednisolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pregnenolone.	Experimental
Probenecid	The serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid.	Approved
Propacetamol	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Propacetamol.	Approved
Propranolol	Meclofenamic acid may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Meclofenamic acid.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Meclofenamic acid.	Experimental
Protein S human	Meclofenamic acid may increase the anticoagulant activities of Protein S human.	Approved
Prulifloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with PTC299.	Investigational
Puromycin	Meclofenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Meclofenamic acid.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Meclofenamic acid.	Approved
Rescinnamine	The risk or severity of adverse effects can be increased when Rescinnamine is combined with Meclofenamic acid.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.	Experimental, Investigational
Reviparin	Meclofenamic acid may increase the anticoagulant activities of Reviparin.	Approved
Ribostamycin	Meclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved
Rimexolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Meclofenamic acid may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rofecoxib.	Investigational, Withdrawn
Rosoxacin	Meclofenamic acid may increase the neuroexcitatory activities of Rosoxacin.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Meclofenamic acid.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Meclofenamic acid.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid.	Experimental
Sisomicin	Meclofenamic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sotalol	Meclofenamic acid may decrease the antihypertensive activities of Sotalol.	Approved
SP1049C	Meclofenamic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.	Investigational
Sparfloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Sparfloxacin.	Approved
Spectinomycin	Meclofenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.	Approved, Vet Approved
Spirapril	The risk or severity of adverse effects can be increased when Spirapril is combined with Meclofenamic acid.	Approved
Spironolactone	Meclofenamic acid may decrease the antihypertensive activities of Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with SRT501.	Investigational
Streptomycin	Meclofenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Streptozocin	Meclofenamic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.	Approved
Sulfasalazine	Meclofenamic acid may increase the nephrotoxic activities of Sulfasalazine.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid.	Approved
Sulodexide	Meclofenamic acid may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Meclofenamic acid.	Investigational
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid.	Approved, Withdrawn
Tacrolimus	Meclofenamic acid may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Meclofenamic acid.	Approved
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Meclofenamic acid.	Approved
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Meclofenamic acid.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m Medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid.	Approved, Investigational
Temafloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Temocapril is combined with Meclofenamic acid.	Experimental, Investigational
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tenofovir.	Approved, Investigational
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Teriflunomide.	Approved
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiludronate.	Approved, Vet Approved
Timolol	Meclofenamic acid may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tinoridine.	Investigational
Tixocortol	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tixocortol.	Approved
Tobramycin	Meclofenamic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid.	Approved
Torasemide	Meclofenamic acid may decrease the diuretic activities of Torasemide.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Meclofenamic acid.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tranilast.	Approved, Investigational
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Meclofenamic acid may decrease the antihypertensive activities of Triamterene.	Approved
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid.	Approved, Vet Approved
Trovafloxacin	Meclofenamic acid may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Withdrawn
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Meclofenamic acid.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Valdecoxib.	Investigational, Withdrawn
Valrubicin	Meclofenamic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid.	Approved, Investigational
Vancomycin	The serum concentration of Vancomycin can be increased when it is combined with Meclofenamic acid.	Approved
Warfarin	Meclofenamic acid may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Meclofenamic acid may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zaltoprofen.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Meclofenamic acid.	Approved, Investigational, Withdrawn
Zoledronic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zoledronic acid.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zomepirac.	Withdrawn
Zorubicin	Meclofenamic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.	Experimental

Food Interactions

Not Available

References

Synthesis Reference

U.S. Patent 3,313,848.

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15074
KEGG Drug	D02341
KEGG Compound	C07117
PubChem Compound	4037
PubChem Substance	46507887
ChemSpider	3897
BindingDB	22971
ChEBI	6710
ChEMBL	CHEMBL509
Therapeutic Targets Database	DNC000919
PharmGKB	PA450341
HET	JMS
Drug Product Database	2114
RxList	http://www.rxlist.com/cgi/generic/meclofen.htm
Wikipedia	Meclofenamic_acid

ATC Codes

M01AG04 — Meclofenamic acid

M02AA18 — Meclofenamic acid

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (74.2 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Enrolling by Invitation	Treatment	Bipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders	1
Not Available	Recruiting	Treatment	Progressive Brain Metastases / Recurrent Brain Metastases	1

Pharmacoeconomics

Manufacturers

Quantum pharmics ltd
American therapeutics inc
Barr laboratories inc
Mylan pharmaceuticals inc
Par pharmaceutical inc
Sandoz inc
Usl pharma inc
Vitarine pharmaceuticals inc
Watson laboratories inc
Parke davis div warner lambert co

Packagers

Dosage forms

Form	Route	Strength
Capsule	Oral	100 mg/1
Capsule	Oral	50 mg/1

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	248-250	U.S. Patent 3,313,848.
water solubility	30 mg/L	MERCK INDEX (1996)
logP	5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00366 mg/mL	ALOGPS
logP	5.11	ALOGPS
logP	6.09	ChemAxon
logS	-4.9	ALOGPS
pKa (Strongest Acidic)	3.79	ChemAxon
pKa (Strongest Basic)	-3.6	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	49.33 Å²	ChemAxon
Rotatable Bond Count	3	ChemAxon
Refractivity	76.45 m³·mol^-1	ChemAxon
Polarizability	28.44 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9393
Blood Brain Barrier	+	0.8668
Caco-2 permeable	+	0.8398
P-glycoprotein substrate	Non-substrate	0.806
P-glycoprotein inhibitor I	Non-inhibitor	0.8943
P-glycoprotein inhibitor II	Non-inhibitor	0.9474
Renal organic cation transporter	Non-inhibitor	0.9094
CYP450 2C9 substrate	Non-substrate	0.6402
CYP450 2D6 substrate	Non-substrate	0.9164
CYP450 3A4 substrate	Non-substrate	0.6566
CYP450 1A2 substrate	Inhibitor	0.9236
CYP450 2C9 inhibitor	Inhibitor	0.9106
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.8271
CYP450 3A4 inhibitor	Non-inhibitor	0.8308
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.558
Ames test	Non AMES toxic	0.8633
Carcinogenicity	Non-carcinogens	0.5329
Biodegradation	Not ready biodegradable	0.9709
Rat acute toxicity	3.0345 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9502
hERG inhibition (predictor II)	Non-inhibitor	0.872

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0006-0090000000-dc6d0aaa7ee199899830	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-052f-0090000000-4f2a28033e59bab0257a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03di-0190000000-b6abcaff657bfa67b599	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03fr-0690000000-eccbe792d08156c89c39	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-0920000000-fdcf8eff9ac77cf86d5b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-0900000000-77140947d50a131a9be6	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-0900000000-5d2a4942eea2a2d2f252	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-004i-0090000000-85032b374ac40bac481a	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-004l-0090000000-a2cbafbde1150bf5812e	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0006-0090000000-47d80abc4f95a2c5ef4c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0006-0090000000-cfa40a800c6a52f6a264	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0006-0290000000-2e34cb2892f6263b39fa	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0563-0980000000-54fb4017b6a67acb639b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-004i-0910000000-26fefd3e49fc0ba3e36e	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0fb9-1900000000-448908b1e79c92a656d7	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0fb9-2900000000-71b13766bf05541800b4	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Benzoic acids and derivatives

Direct Parent

Aminobenzoic acids

Alternative Parents

Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Dichlorobenzenes / Benzoyl derivatives / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives

Substituents

Aminobenzoic acid / Benzoic acid / Benzoyl / 1,3-dichlorobenzene / Aniline or substituted anilines / Aminotoluene / Toluene / Chlorobenzene / Halobenzene / Aryl chloride

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:6710 )

Targets

Details

1. Prostaglandin G/H synthase 1

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Prostaglandin-endoperoxide synthase activity
Specific Function:: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:: PTGS1
Uniprot ID:: P23219
Molecular Weight:: 68685.82 Da

References

Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. [PubMed:12225961 ]
Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83. [PubMed:11094641 ]
Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181 ]
Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4. [PubMed:8454631 ]

Details

2. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Prostaglandin-endoperoxide synthase activity
Specific Function:: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:: PTGS2
Uniprot ID:: P35354
Molecular Weight:: 68995.625 Da

References

Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181 ]
Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45. [PubMed:12409963 ]
Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14. [PubMed:16290292 ]
Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. [PubMed:7825862 ]

Details

3. Arachidonate 5-lipoxygenase

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Iron ion binding
Specific Function:: Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:: ALOX5
Uniprot ID:: P09917
Molecular Weight:: 77982.595 Da

References

Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34. [PubMed:1539679 ]
Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38. [PubMed:3020588 ]

Details

4. Potassium voltage-gated channel subfamily KQT member 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: other

General Function:: Voltage-gated potassium channel activity
Specific Function:: Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic in...
Gene Name:: KCNQ2
Uniprot ID:: O43526
Molecular Weight:: 95846.575 Da

References

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972 ]

Details

5. Potassium voltage-gated channel subfamily KQT member 3

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: other

General Function:: Voltage-gated potassium channel activity
Specific Function:: Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to sy...
Gene Name:: KCNQ3
Uniprot ID:: O43525
Molecular Weight:: 96741.515 Da

References

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972 ]

Transporters

Details

1. Solute carrier family 22 member 6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:: SLC22A6
Uniprot ID:: Q4U2R8
Molecular Weight:: 61815.78 Da

References

Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]

Details

2. Solute carrier organic anion transporter family member 1C1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Thyroid hormone transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:: SLCO1C1
Uniprot ID:: Q9NYB5
Molecular Weight:: 78695.625 Da

References

Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642 ]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:54

Get DrugBank to go!

Structure for DB00939 (Meclofenamic acid)

Targets

References

References

References

References

References

Transporters

References

References